Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron R Hansen

Showing results (41-50 of 172) with videos related to

Pageof 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 8, 2019
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinomaRicard Mesia, Paolo Bossi, Aaron R Hansen, et al.
Journal of the National Cancer Institute|February 22, 2021
Underreporting of Symptomatic Adverse Events in Phase I Clinical TrialsZachary W Veitch, Daniel Shepshelovich, Christina Gallagher, et al.
Oral Oncology|January 17, 2022
Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinomaOlivia Chin, Laila Alshafai, Brian O'Sullivan, et al.
Investigational New Drugs|March 14, 2024
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumorsMaxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, et al.
Targeted Oncology|May 31, 2022
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket StudyAbdulazeez Salawu, Aaron R Hansen, Anna Spreafico, et al.
Cancer Medicine|December 17, 2021
Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancerEoghan R Malone, Jeremy Lewin, Xuan Li, et al.
Cancer|April 2, 2021
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancerShabbir M H Alibhai, Henriette Breunis, Aaron R Hansen, et al.
JCO Precision Oncology|August 2, 2021
Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive TreatmentNazanin Aghel, Dakota Gustafson, Ashley Di Meo, et al.
Head & Neck|April 26, 2020
Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancerChristopher W Noel, Robert F Stephens, Jie Susie Su, et al.
Head & Neck|November 26, 2019
Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancerRobert F Stephens, Christopher W Noel, Jie Susie Su, et al.
Pageof 18

Showing results (41-50 of 172) with videos related to

Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|November 8, 2019
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinomaRicard Mesia, Paolo Bossi, Aaron R Hansen, et al.
Journal of the National Cancer Institute|February 22, 2021
Underreporting of Symptomatic Adverse Events in Phase I Clinical TrialsZachary W Veitch, Daniel Shepshelovich, Christina Gallagher, et al.
Oral Oncology|January 17, 2022
Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinomaOlivia Chin, Laila Alshafai, Brian O'Sullivan, et al.
Investigational New Drugs|March 14, 2024
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumorsMaxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, et al.
Targeted Oncology|May 31, 2022
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket StudyAbdulazeez Salawu, Aaron R Hansen, Anna Spreafico, et al.
Cancer Medicine|December 17, 2021
Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancerEoghan R Malone, Jeremy Lewin, Xuan Li, et al.
Cancer|April 2, 2021
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancerShabbir M H Alibhai, Henriette Breunis, Aaron R Hansen, et al.
JCO Precision Oncology|August 2, 2021
Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive TreatmentNazanin Aghel, Dakota Gustafson, Ashley Di Meo, et al.
Head & Neck|April 26, 2020
Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancerChristopher W Noel, Robert F Stephens, Jie Susie Su, et al.
Head & Neck|November 26, 2019
Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancerRobert F Stephens, Christopher W Noel, Jie Susie Su, et al.
Pageof 18